

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re Application of: A

Ashok TEHIM et al.

Serial No.: 10/669,645

Group Art Unit: 1614

Filed: September 25, 2003

Examiner: Unassigned

For: INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND

PREPARATION AND USES THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

MAIL STOP AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

\boxtimes		Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information disclosure statement is filed:			
			n three months of the filing date of a national application other than a CPA § 1.53(d);		
			n three months of the actual filing date of the national phase of a PCT cation; OR		
	\boxtimes	before RCE)	e the mailing of a first substantive office action (including after filing of an		
			C.R. § 1.97(c), this information disclosure statement is filed after the periods of C.F.R. § 1.97(b), but before the mailing date of:		
			a final rejection under 37 C.F.R. 1.113;		
			termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR		
			a notice of allowance under 37 C.F.R. § 1.311; and		

		is acco	ompanied by:		
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR		
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).		
			R. § 1.97(d), this information disclosure statement is filed after the mailing llowing actions which have not been withdrawn:		
			a final action under 37 C.F.R. § 1.113;		
			termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR		
			a notice of allowance under 37 C.F.R. § 1.311;		
	AND	is filed	on or before payment of the issue fee; AND is accompanied by:		
			the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).		
Stater	nents U	<u>nder 37</u>	C.F.R. 1.97(e)		
			Each item of information contained in this information disclosure statement was a first cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or		
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.		
Cited	Materia	<u>lls</u>			
		Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No, on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).			
			s of materials listed and are attached (except for US references) were cited nternational search report dated		

		Copies of the materials listed are attached).
Non-E	nglish l	Language References
		An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
		A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
		 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document
		A = document defining the general state of the art
		O = non-written disclosure
		 P = intercalated document T = document cited to understand the theory or principle underlying the
		invention
		E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
		D = cited in the application
		L = cited for another reason
		& = publication of member of same patent family
		Translation of other relevant information on foreign search report
Other 1	Informa	<u>ution</u>
<u>Payme</u>	nt of Fe	ees Due (If Any):
	A chec	ck for \$ covering the fee identified above is attached.
	Please	charge to Deposit Account No. 13-3402 \$ for the fee identified above.

 \boxtimes The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

P. Heaney, Reg. No. 32,542 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: MEMORY-33

Date: February 16, 2005

BPH/rrt



Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE or respond to a collection of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to res

Substitut	te for form 1449A/F	РТО		Complete if Known		
				Application Number	10/669,645	
INFO	DRMATIO	N DISCI	LOSURE	Filing Date	September 25, 2003	
STA	TEMENT	BY APP	LICANT	First Named Inventor	Ashok Tehim	
				Group Art Unit	1614	
	(use as many s	sheets as ned	essary)	Examiner Name	Unassigned	
Sheet	1	of	1	Attorney Docket Number	MEMORY-33	

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No.1	U.S. Patent Document Kind Code ² Number (<i>if known</i>)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
		6,780,861		Nozulak	8/24/04	
					<u> </u>	

	FOREIGN PATENT DOCUMENTS								
		Foreign Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant			
Examiner Initials*	Cite No.1	Office ³	Number⁴	Kind Code ⁵ (<i>if known</i>)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T⁵	
			i						

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т:				

Examiner Signature	Date Considered
	· · · · · · · · · · · · · · · · · · ·

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Palant and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 2 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. And of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language Translation is attached.